Dulaglutide is a novel glucagon-like peptide-1 agonist (GLP-1) biologic drug consisting of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker.
CAT No:10-101-159
CAS No:923950-08-7
Synonyms/Alias:LY2189265
Quick InquiryPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C2646H4044N704O836S18 |
M.W/Mr. | 59669.8068 |
Labeling Target | Glucagon-like peptide-1 (GLP-1) receptor |
Application | Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
Activity | Agonist |
Biological Activity | Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist that augments glucose-dependent insulin secretion, and slows gastric emptying. |
Areas of Interest | Metabolic Disease |
Functions | Transmembrane signaling receptor activity |
Target | GLP-1 Receptor |
Long-term Storage Conditions | Soluble in DMSO |
Shipping Condition | Room temperature |
Organism | Human |
BoilingPoint | N/A |
References | Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial, we compared the safety and efficacy of once-weekly dulaglutide with that of once-daily liraglutide in metformin-treated patients with uncontrolled type 2 diabetes. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial To compare efficacy and safety of dulaglutide, a once weekly glucagon-like peptide1 receptor agonist, to placebo and exenatide in type 2 diabetes patients. Primary objective was superiority of dulaglutide 1.5 mg versus placebo in HbA1c change at 26 weeks. Efficacy and Safety of Dulaglutide Added on to Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1) |
Melting Point | N/A |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.